Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hundreds of dietary supplements have been reported to improve cognitive and emotional function in humans, but few have scientific foundation. A new study from the Department of Physiology, Anatomy & Genetics (DPAG) provides fresh insight into how dietary magnesium supplementation can influence memory performance.

Fluorescent close up of the fly brain showing that a key magnesium transporter dominates the neurons involved in memory.
The fly CNNM protein (green, shown to cover the entire area) is abundant in memory-relevant neurons in the fly brain

Prior research has shown that supplementing the diet of young and aging rodents with Magnesium improves their memory and it even appears to partially restore memory deficits in animals harbouring models of Alzheimer’s disease. Magnesium may therefore have therapeutic potential for humans with memory issues.

Yanying Wu, a Postdoctoral Fellow in DPAG's Waddell group, first showed that Magnesium feeding also improved memory of fruit flies (Drosophila). According to Professor Scott Waddell: “We reasoned that if Magnesium enhanced fly memory, this would indicate that it is a general feature of memory systems, and would allow us to analyse the underlying biology." Importantly, the memory-enhancing effects of Magnesium appear to involve a different mechanism to that previously proposed in rodents. The Waddell group found that a conserved Magnesium transporter (known as a Cyclin M2 or CNNM protein) was essential for normal and Magnesium-enhanced memory. Magnesium feeding increased the levels of Magnesium in memory-relevant neurons and the CNNM transporter is critical to regulate these elevated levels.

The full story is available on the Department of Physiology, Anatomy & Genetics website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.